Raw Materials for COVID-19 Cell Therapy Development

The worldwide spread of the COVID-19 pandemic and its severe health consequences have created the need to find novel treatments rapidly. Cell-based approaches using mesenchymal stem cells (MSCs), natural killer (NK) cells or virus-specific T cells have been proposed as a suitable therapy and several clinical trials have already begun.

In an effort to support the development of these novel cell therapies, we offer special COVID-19 discount packages of our high quality raw materials. Please contact your local sales manager to discuss your raw material needs.

 

Here we present an overview of the relevant raw materials to make it easier to find what you need:

MSC

Mesenchymal stem cells (MSCs) exert a profound immunomodulatory effect on the immune system.

MSCs-based immunomodulation treatment is one of the most promising treatment options to prevent the severe acute respiratory infection form of COVID-19, the most dangerous phase of this disease. This has triggered a growing interest in MSCs as a potential supportive therapy for patients with severe complications of coronavirus infection.

NK CELLS

Natural Killer (NK) cells are a subset of cytotoxic lymphocytes involved in the innate immune system.

NK cell therapies have been proposed to keep the coronavirus from replicating out of control, thereby buying enough time for the immune system to start producing its own specialized cells and permanently suppress the infection.

T CELLS

T cells play a central role in cell-mediated immunity.

Virus-specific cytotoxic T cells can rapidly reconstitute antiviral immunity. An immunotherapy with SARS-CoV-2-specific T cells could potentially restore natural T cell immunity against COVID-19 in immunocompromised patients.

 

We offer the following raw materials in preclinical and GMP grade to support the development of MSCs-based therapies for COVID-19:

We offer the following raw materials in preclinical and GMP grade to support the development of NK cell therapies for COVID-19:

We offer the following raw materials in preclinical and GMP grade to support the development of T cell therapies for COVID-19: